CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 27, 2010
Result type: Reports
Project Number: SR0213-000
Product Line: Reimbursement Review

Generic Name: Febuxostat

Brand Name: Uloric

Manufacturer: Takeda Canada Inc.

Therapeutic Area: Gout

Indications: Gout

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 25, 2011

Recommendation Type: List with clinical criteria and/or conditions